SA PRO
Free Account
Insmed IncorporatedINSMNASDAQ
LOADING
|||
OverviewNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 92% recommend buying.

Consensus Rating
Buy
25 analysts·High coverage
92%
Rating Distribution
Strong Buy
00%
Buy
2392%
Hold
28%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 12, 2026Truist Financial
Truist on Insmed (INSM): Brinsupri Launch Outpacing Most Bullish Expectations
Target:$205.00
+23.3%from $166.25
Jan 8, 2026Morgan Stanley
Insmed price target lowered to $157 from $158 at Morgan Stanley
Target:$157.00
-10.8%from $176.00
Jan 6, 2026UBS
Insmed price target lowered to $215 from $223 at UBS
Target:$215.00
+24.0%from $173.34
Dec 19, 2025Truist Financial
Insmed assumed with a Buy at Truist
Target:$202.00
+21.3%from $166.55
Dec 18, 2025H.C. Wainwright
Insmed price target lowered to $230 from $240 at H.C. Wainwright
Target:$230.00
+38.6%from $165.99
Dec 18, 2025Cowen & Co.
Insmed price target lowered to $241 from $269 at TD Cowen
Target:$241.00
+43.9%from $167.53
Dec 18, 2025Mizuho Securities
Insmed (INSM) PT Lowered to $212 at Mizuho, 'We're Buyers on Weakness'
Target:$212.00
+26.4%from $167.71
Dec 18, 2025Guggenheim
Insmed price target lowered to $221 from $230 at Guggenheim
Target:$221.00
+11.4%from $198.46
Dec 18, 2025Wedbush
Insmed (INSM) PT Lowered to $203 at BofA Securities
Target:$203.00
+21.4%from $167.22
Dec 18, 2025RBC Capital
Insmed (INSM) PT Lowered to $195 at RBC Capital
Target:$195.00
-1.7%from $198.46
Dec 18, 2025Wells Fargo
Insmed (INSM) PT Lowered to $195 at Leerink Partners
Target:$195.00
-1.7%from $198.46
Dec 18, 2025Wolfe Research
Insmed (INSM) PT Lowered to $167 at Wolfe Research
Target:$167.00
-15.9%from $198.46
Dec 16, 2025Wells Fargo
Insmed price target raised to $234 from $217 at Wells Fargo
Target:$234.00
+18.9%from $196.85
Dec 16, 2025Cantor Fitzgerald
Insmed (INSM) PT Raised to $230 at Cantor Fitzgerald Brenso Potential
Target:$230.00
+16.8%from $196.85
Dec 10, 2025Jefferies
'Insmed's (INSM) Quad Shot At Significant Upside'; PT Raised to $269 at TD Cowen
Target:$269.00
+38.3%from $194.51
Dec 4, 2025Redburn Partners
Insmed initiated with a Buy at Rothschild & Co Redburn
Target:$263.00
+27.2%from $206.78
Dec 1, 2025Mizuho Securities
Insmed (INSM) PT Raised to $256 at Mizuho
Target:$256.00
+23.2%from $207.77
Oct 31, 2025Goldman Sachs
Insmed price target raised to $225 from $196 at Goldman Sachs
Target:$225.00
+18.2%from $190.30
Oct 31, 2025RBC Capital
Insmed price target raised to $215 from $139 at RBC Capital
Target:$215.00
+10.5%from $194.57
Oct 31, 2025UBS
Insmed price target raised to $223 from $194 at UBS
Target:$223.00
+14.9%from $194.00
Oct 31, 2025Wells Fargo
Insmed price target raised to $217 from $171 at Wells Fargo
Target:$217.00
+11.7%from $194.22
Oct 29, 2025Mizuho Securities
Insmed price target raised to $196 from $165 at Mizuho
Target:$196.00
+17.4%from $166.97
Oct 28, 2025Cantor Fitzgerald
Insmed assumed with an Overweight at Cantor Fitzgerald
Target:$192.00
+15.1%from $166.77
Oct 14, 2025UBS
Insmed price target raised to $194 from $140 at UBS
Target:$194.00
+18.3%from $163.94
Oct 1, 2025Evercore ISI
Insmed price target raised to $180 from $110 at Evercore ISI
Target:$180.00
+23.0%from $146.31

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance